期刊文献+

超滤法测定伊立替康脂质体包封率的研究 被引量:18

Studies on entrapment efficiency of irinotecan liposomes by ultrafiltration method
在线阅读 下载PDF
导出
摘要 目的:以超滤法对伊立替康(CPT-11)脂质体包封率的测定方法进行研究。方法:采用薄膜蒸发-高压乳匀法制备CPT-11脂质体,以超滤法分离脂质体和游离药物,建立 HPLC 测定 CPT-11含量的方法。结果:超滤法能将脂质体与游离药物很好地分离,药物回收率为99.3%~100.9%,加样回收率为99.6%~102.5%。在选定色谱条件下,CPT-11分离良好,在0.106~1.012 mg·mL^(-1)范围内呈良好的线性关系(r=0.9996),日内 RSD 为1.6%,日间 RSD 为2.3%(n=5),回收率为97.7%~100.4%,。RSD 为1.1%~2.3%。结论:采用超滤-HPLC 法能较好测定 CPT-11脂质体的含量及包封率,同时具有简单、准确、快速的优点。 Objective : To study the entrapment efficiency of irinotecan ( CPT - 11 ) liposome by ultrafiltration meth- od. Methods:Uhrafiltration method was employed to separate the free drug from the liposomes. The content of CPT - 11 was determined by a HPLC method. Results:The free drug was well separated from the liposome by ultrafiltra- tion method. The drug recovery by ultrafiltration was in a range of 99. 3% - 100.9% , the sample recovery was 99.6% - 102.5%, respectively. A calibrated linear curve of CPT - 11 concentration was within 0. 106 - 1. 012 mg · mL-1( r =0. 9996) ,and RSD within day was 1.6% and RSD between days was 2.3% ( n =5) ,the recovery of CPT- 11 was in a range of 97.7% -100. 4% with RSD of 1.1% -2.3%. Conclusion:The ultrafiltration method used in this study is simple, accurate and applicable for determination entrapment efficiency of CPT - 11.
出处 《药物分析杂志》 CAS CSCD 北大核心 2008年第12期2081-2084,共4页 Chinese Journal of Pharmaceutical Analysis
关键词 超滤法 包封率 伊立替康 脂质体 ultrafihration entrapment efficiency irinotecan ( CPT - 11 ) liposomes
作者简介 通讯作者Tel:(025)83271272;Fax:(025)83301606;E—mail:yaoj3@163.com
  • 相关文献

参考文献7

  • 1Nicola F. Smith, William D, Figg Alex Sparreboom. Pharmacogenetics of irinotecan metabolism and transport : An update. Toxicol in Vitro, 2006 ( 20 ) : 163.
  • 2PINGQi-neng(平其能).Modem Phannaceutics(现代药剂学),Beijing(北京):ChinaMedico-Pharmaceutical Scienceand Technology Publishing House(中国医药科技出版社),1998.608.
  • 3Gregor lad, Is G. Liposome Technology Volume I, Liposome Preparation and Related Techniques. Second edition. London, England: CRC press, 1993:585.
  • 4Paul G. Tardi, Ryan C, Gallaghera, et al. Coencapsulation of irinotecan and floxuridine into low cholesterol - containing liposomes that coordinate drug release in vivo. Bioehimica et Biophysica Acta ,2007:678.
  • 5狄斌,冯芳,李玉艳,于立洁,宋华琳,张正行.抗癌新药伊立替康含量测定方法的研究[J].药物分析杂志,1999,19(5):293-296. 被引量:4
  • 6李宝齐,邓英杰,杨静文.超滤-HPLC法测定盐酸拓扑替康脂质体包封率[J].中国新药杂志,2007,16(1):58-61. 被引量:15
  • 7Oh Ws, Park HY. Improvement of permeate flux by turbulence promot- er and development of mass transfer correlation in UF. Off Proc Comb 6^th Conf Asia Pae Confed Chem Eng 21st Australias. Chem Eng conf, 1993,1:359.

二级参考文献8

  • 1郝艳丽,邓英杰,陈妍,王秀敏.盐酸拓扑替康脂质体的制备及影响因素考察[J].中国药学杂志,2004,39(8):602-604. 被引量:7
  • 2FASSBERG J,STELLA VJ.A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues[J].J Pharm Sci,1992,81 (7):676-684.
  • 3LIU JJ,HONG RL,CHENG WF,et al.Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient:stability,pharmacokinetic and therapeutic evaluation[J].Anticancer Drugs,2002,13(7):709 -717.
  • 4ABRAHAM SA,EDWARDS K,KARLSSON G,et al.An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes[J].J Controlled Release,2004,96(3):449 -461.
  • 5GREGORIADIS G.Liposome Technology Volume I,Liposome Preparation and Related Techniques[M].Second edition.London,England:CRC press,1993:585-586.
  • 6ALBERT SK,KAMLESH P,NAGESH RP,et al.Preformulation studies to aid in the development of a ready-to-use injectable solution of the antitumor agent,topotecan[J].Int J Pharm,1996,127(2):229 -237.
  • 7戴建国,赵俊,赵小伟.注射用盐酸拓扑替康的质量分析方法研究[J].中国新药杂志,2003,12(8):638-640. 被引量:5
  • 8张秀国,雍政,张谦,赵水明.拓扑替康在临床应用的研究进展[J].中国新药与临床杂志,2003,22(11):691-696. 被引量:6

共引文献17

同被引文献2111

引证文献18

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部